相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
Ru Zhou et al.
FRONTIERS IN IMMUNOLOGY (2019)
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
Jeffrey J. Ishizuka et al.
NATURE (2019)
Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles
Shu-ta Wu et al.
BMC CANCER (2018)
TIM-3, a promising target for cancer immunotherapy
Yayi He et al.
ONCOTARGETS AND THERAPY (2018)
Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype
Mirna Swayden et al.
HELIYON (2018)
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells
Lynsey M. Whilding et al.
MOLECULAR THERAPY (2017)
The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells
Isabel Goncalves Silva et al.
EBIOMEDICINE (2017)
Pancreatic Cancer: A Review
Cinthya S. Yabar et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2016)
Mucin-1-Antibody-Conjugated Mesoporous Silica Nanoparticles for Selective Breast Cancer Detection in a Mucin-1 Transgenic Murine Mouse Model
Didier Dreau et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2016)
A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis
R. Zhou et al.
ONCOGENE (2016)
Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Daniel Delitto et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
Fengtao You et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors
Laura Jeffords Moore et al.
TRANSLATIONAL ONCOLOGY (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Cyclooxygenase-2: A Role in Cancer Stem Cell Survival and Repopulation of Cancer Cells during Therapy
Lisa Y. Pang et al.
STEM CELLS INTERNATIONAL (2016)
A Perspective of Immunotherapy for Prostate Cancer
Ida Silvestri et al.
CANCERS (2016)
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
Soranobu Ninomiya et al.
BLOOD (2015)
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Santiago Zelenay et al.
CELL (2015)
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes
Manuel Hidalgo et al.
PANCREATOLOGY (2015)
Engineering CAR-T cells: Design concepts
Shivani Srivastava et al.
TRENDS IN IMMUNOLOGY (2015)
A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme
Gilli Galore-Haskel et al.
ONCOTARGET (2015)
Apoptosis of tumor infiltrating effector TIM-3+CD8+T cells in colon cancer
Chiao-Wen Kang et al.
SCIENTIFIC REPORTS (2015)
Tryptophan-degrading enzymes in tumoral immune resistance
Nicolas van Baren et al.
FRONTIERS IN IMMUNOLOGY (2015)
Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells
Usanarat Anurathapan et al.
MOLECULAR THERAPY (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Michael Hudecek et al.
CLINICAL CANCER RESEARCH (2013)
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Liza B. John et al.
CLINICAL CANCER RESEARCH (2013)
IDO1 Metabolites Activate β-catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice
Ameet I. Thaker et al.
GASTROENTEROLOGY (2013)
The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer
Jennifer M. Curry et al.
JOURNAL OF SURGICAL ONCOLOGY (2013)
Galectin-9 Functionally Impairs Natural Killer Cells in Humans and Mice
Lucy Golden-Mason et al.
JOURNAL OF VIROLOGY (2013)
Galectin-9 in Cancer Therapy
Shintaro Fujihara et al.
RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9
Michelle K. Gleason et al.
BLOOD (2012)
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Scott Wilkie et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Regulation of Immune Responses by Prostaglandin E-2
Pawel Kalinski
JOURNAL OF IMMUNOLOGY (2012)
MUC1 regulates PDGFA expression during pancreatic cancer progression
M. Sahraei et al.
ONCOGENE (2012)
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor
Scott Wilkie et al.
JOURNAL OF IMMUNOLOGY (2008)
Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions
Keiko Nagahara et al.
JOURNAL OF IMMUNOLOGY (2008)
Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma
Nobusada Koike et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Cytotoxic T lymphocyte-induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis
NJ Waterhouse et al.
JOURNAL OF CELL BIOLOGY (2006)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
ME Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
MUC1 and MUC2 in pancreatic neoplasia
E Levi et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation
JA Schroeder et al.
ONCOGENE (2004)
MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration
DC Chhieng et al.
CANCER CYTOPATHOLOGY (2003)
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase
G Frumento et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells:: Mediation of suppression by tryptophan metabolites
P Terness et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation
P Hwu et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
